Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
NEW YORK, March 02, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Cardiovascular Systems, Inc. (“Cardiovascular Systems”) (NASDAQ:CSII) between September 12, 2011 and January 21, 2016.
You are hereby notified that a securities class action has been commenced in the USDC for the Central District of California. If you purchased or otherwise acquired Cardiovascular Systems securities between September 12, 2011 and January 21, 2016, your rights may be affected by this action. To get more information go to: http://zlk.9nl.com/cardiovascular-systems.
The complaint alleges that throughout the Class Period Defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Cardiovascular Systems distributed illegal kickbacks to health care providers; (2) Cardiovascular Systems engaged in the off-label promotion of its medical devices; and (3) Cardiovascular Systems violated FDA laws and regulations in connection with its medical devices. As a result of the foregoing, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Cardiovascular Systems you have until April 12, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/cardiovascular-systems.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
